The Effect of Zinc Acetate Lozenges on the Rate of Recovery From the Common Cold

Respiratory Tract Infections Clinical Trial

— HelZinki  

Official title:

The Effect of Zinc Acetate Lozenges on the Rate of Recovery From the Common Cold: a Randomized Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03309995
• Other study ID #: HelZinki Study
• Status: Completed
• Phase: N/A
• Start date: December 1, 2017
• Est. completion date: September 24, 2018

Study information

• Verified date: January 2020
• Source: Helsinki University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized parallel-group two arm superiority trial with an allocation ratio 1:1, both participants and investigators blinded.

The zinc lozenge that will be used in the study is a commercial product available from the University Pharmacy, Helsinki, Finland. The product is classified as a "medical device" and it is not regulated according to the jurisdiction for medicines.

Each lozenge contains 13 mg elemental zinc as zinc acetate. The instruction in the commercial package for common cold patients is to dissolve slowly 6 lozenges per day in their mouth, which totals to 78 mg/day of elemental zinc, at most for 5 days. The same instruction will be used in this trial.

The University Pharmacy prepared 200 placebo lozenge packages so that the placebo lozenges contain sucrose octaacetate, and they are similar with the zinc lozenges in visual appearance and in taste. 200 packages of zinc lozenges will be used as the active intervention. The packages will contain 30 lozenges (6 lozenges/day × 5 days).

The packages of lozenges will be distributed to the enrolled participants in November 2017. The participants will be instructed to keep the package readily available so that, when they catch the common cold, they will find the package and they can start to take the lozenges according to the instructions.

The participants will be instructed to start taking zinc lozenges as soon as they start to suffer from the first symptoms of the common cold. The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible. The duration of intervention is for the maximum of 5 days. If the symptoms disappear before 5 days, the participant may stop the usage of the lozenges.

There will be no limitations for other treatments that participants wish to use for treating their colds.

Participants will be requested to respond to a web-based symptom questionnaire daily from the first day of the treatment to the recovery from the common cold, or to a maximum of 2 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 87
• Est. completion date: September 24, 2018
• Est. primary completion date: April 24, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• =18 years, recollecting that they usually have had =1 colds per winter.

Exclusion Criteria:

• pregnancy or lactation; chronic runny nose or chronic cough.

Related Conditions & MeSH terms

• Common Cold
• Respiratory Tract Infections

Intervention

Device:
• Lozenges
The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
• Placebo lozenges
Placebo lozenges

Locations

Country	Name	City	State
Finland	City of Helsinki	Helsinki

Sponsors (2)

Lead Sponsor	Collaborator
Helsinki University	The University Pharmacy, Helsinki

Country where clinical trial is conducted

Finland, 

References & Publications (1)

Hemilä H, Haukka J, Alho M, Vahtera J, Kivimäki M. Zinc acetate lozenges for the treatment of the common cold: a randomised controlled trial. BMJ Open. 2020 Jan 23;10(1):e031662. doi: 10.1136/bmjopen-2019-031662. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The duration of the common cold (time to recovery)	Data of 12 common cold symptoms will be recorded by patients to web-based system, with scale 0: Absent, 1: Mild, 2: Moderately severe, 3: Very severe symptom. The symptom score is calculated as a sum over all the symptoms which means that the maximum of the symptom score scale is 3×12 = 36 points. Recovery from the cold is defined as the day when the symptom score is 0 or 1.	2 weeks after the start of the intervention
Secondary	Objective fever	Measured fever (=37.5°C any time during the day) (Yes / No)	2 weeks after the start of the intervention
Secondary	Sickness absence	Data will be collected of the absence from work after the start of intervention	About 1 month after the start of the intervention
Secondary	Usage of antibiotics and/or asthma medication	Data will be collected of the usage of antibiotics and/or asthma medication after the start of intervention	About 1 month after the start of the intervention
Secondary	Complications such as sinusitis, bronchitis, otitis.	Data will be collected of the occurrence of sinusitis, bronchitis, otitis after the start of intervention	About 1 month after the start of the intervention

External Links

•   Report of the trial